Abstract
β-catenin activation, and subsequent upregulation of Wnt-signaling, is an important event in the development of certain human and rodent cancers. Recently, mutations in the β-catenin gene in the region of the serine-threonine glycogen kinase (GSK)-3β phosphorylation target sites have been identified in hepatocellular neoplasms from humans and transgenic mice. In this study we examined 152 hepatocellular neoplasms from B6C3F1 mice included in five chemical treatment groups and controls for mutations in the β-catenin gene. Twenty of 29 hepatocellular neoplasms from mice treated with methyleugenol had point mutations at codons 32, 33, 34 or 41, sites which are mutated in colon and other cancers. Likewise, nine of 24 methylene chloride-induced hepatocellular neoplasms and 18 of 42 oxazepam-induced neoplasms exhibited similar mutations. In contrast, only three of 18 vinyl carbamate-induced liver tumors, one of 18 TCDD-induced liver tumors, and two of 22 spontaneous liver neoplasms had mutations in β-catenin. Thus, there appears to be a chemical specific involvement of β-catenin activation in mouse hepatocellular carcinogenesis. Expression analyses using Western blot and immunohistochemistry indicate that β-catenin protein accumulates along cell membranes following mutation. The finding of mutations in both adenomas and carcinomas from diverse chemical treatment groups and the immunostaining of β-catenin protein in an altered hepatocellular focus suggest that these alterations are early events in mouse hepatocellular carcinogenesis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Aberle H, Bauer A, Stappert J, Kispert A and Kemler R. . 1997 EMBO J. 16: 3797–3804.
Dashwood RH, Suzui M, Nakagama H, Sugimura T and Nagao M. . 1998 Cancer Res. 58: 1127–1129.
Davis LM, Caspary WJ, Sakallah SA, Maronpot R, Wiseman R, Barrett JC, Elliott R and Hozier JC. . 1994 Carcinogenesis 15: 1637–1645.
de La Coste A, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane O, Fabre M, Chelly J, Beldjord C, Kahn A and Perret C. . 1998 Proc. Natl. Acad. Sci. USA 95: 8847–8851.
Devereux TR, Foley JF, Maronpot RR, Kari F and Anderson MW. . 1993 Carcinogenesis 14: 795–801.
Devereux TR, White CM, Sills RC, Bucher JR, Maronpot RR and Anderson MW. . 1994 Carcinogenesis 15: 1083–1087.
Fujimori M, Tokino T, Hino O, Kitagawa T, Imamura T, Okamoto E, Mitsunobu M, Ishikawa T, Nakagama H and Harada H, et al. 1991 Cancer Res. 51: 89–93.
Fukuchi T, Sakamoto M, Tsuda H, Maruyama K, Nozawa S and Hirohashi S. . 1998 Cancer Res. 58: 3526–3528.
Gresani KM, Rollins LA, Leone-Kabler S, Cline JM and Miller MS. . 1998 Carcinogenesis 19: 1045–1052.
Gumbiner BM. . 1997 Curr. Biol. 7: R443–R446.
He T-C, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B and Kinzler KW. . 1998 Science 281: 1509–1512.
Horii A, Nakatsuru S, Miyoshi Y, Ichii S, Nagase H, Ando H, Yanagisawa A, Tsuchiya E, Kato Y and Nakamura Y. . 1992 Cancer Res. 52: 6696–6698.
Jen J, Powell SM, Papadopoulos N, Smith KJ, Hamilton SR, Vogelstein B and Kinzler KW. . 1994 Cancer Res. 54: 5523–5526.
Kari F, Foley J, Seilkop S, Maronpot R and Anderson M. . 1993 Carcinogenesis 14: 819–826.
Kinzler KW and Vogelstein B. . 1996 Cell 87: 159–170.
Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B and Clevers H. . 1997 Science 275: 1784–1787.
Manenti G, De Gregorio L, Gariboldi M, Dragani TA and Pierotti MA. . 1995 Mol. Carcin. 13: 191–200.
Marmur J. . 1961 J. Mol. Biol. 3: 208–218.
Maronpot RR, Fox T, Malarkey DE and Goldsworthy TL. . 1995 Toxicology 101: 125–156.
Miyoshi Y, Iwao K, Nagasawa Y, Aihara T, Sasaki Y, Imaoka S, Murata M, Shimano T and Nakamura Y. . 1998 Cancer Res. 58: 2524–2527.
Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B and Kinzler KW. . 1997 Science 275: 1787–1790.
Munemitsu S, Albert I, Souza B, Rubenfeld B and Polakis P. . 1995 PNAS 92: 3046–3050.
Orford K, Crockett C, Jenson JP, Weissman AM and Byers SW. . 1997 J. Biol. Chem. 272: 24735–24738.
Peifer M. . 1997 Science 275: 1752–1753.
Pennisi E. . 1998 Science 281: 1438–1441.
National Toxicology Program. . 1993 NTP TR #443 U.S. Dept. HHS, PHS, NIH, RTP, NC.
Rubinfeld B, Albert I, Porfiri E, Munemitsu S and Polakis P. . 1997 Cancer Res. 57: 4624–4630.
Rubinfeld B, Albert I, Porfiri EFC, Munemitsu S and Polakis P. . 1996 Science 272: 1023–1026.
Takahashi M, Fukuda K, Sugimura T and Wakabayashi K. . 1998 Cancer Res. 58: 42–46.
Watson MA, Devereux TR, Malarkey DE, Anderson MW and Maronpot RR. . 1995 Carcinogenesis 16: 1705–1710.
Wiseman R, Stowers S, Miller E, Anderson M and Miller J. . 1986 Proc. Natl. Acad. Sci. USA 83: 5825–5829.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Devereux, T., Anna, C., Foley, J. et al. Mutation of β-catenin is an early event in chemically induced mouse hepatocellular carcinogenesis. Oncogene 18, 4726–4733 (1999). https://doi.org/10.1038/sj.onc.1202858
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1202858
Keywords
This article is cited by
-
A combined bioinformatics and experimental approach identifies RMI2 as a Wnt/β-catenin signaling target gene related to hepatocellular carcinoma
BMC Cancer (2023)
-
p53 triggers mitochondrial apoptosis following DNA damage-dependent replication stress by the hepatotoxin methyleugenol
Cell Death & Disease (2022)
-
Genetic ablation of β-catenin inhibits the proliferative phenotype of mouse liver adenomas
British Journal of Cancer (2014)
-
Phenotype of single hepatocytes expressing an activated version of β-catenin in liver of transgenic mice
Journal of Molecular Histology (2011)
-
Promotion of hepatocarcinogenesis in humans and animal models
Archives of Toxicology (2008)